Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
GPCR Stock Chart & Stats
$53.75
-$0.32(-1.18%)
At close: 4:00 PM EST
$53.75
-$0.32(-1.18%)
Day’s Range― - ―
52-Week Range$13.22 - $94.90
Previous CloseN/A
Volume219.80K
Average Volume (3M)858.08K
Market Cap
$3.81B
Enterprise Value$2.30B
Total Cash (Recent Filing)$1.45B
Total Debt (Recent Filing)$6.49M
Price to Earnings (P/E)31.2
Beta1.25
Next Earnings
May 07, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding70,841,810
10 Day Avg. Volume813,279
30 Day Avg. Volume858,075
Financial Highlights & Ratios
PEG Ratio-11.37
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-18.23
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.35K
Enterprise Value/Ebitda-14.57
Forecast
1Y Price Target
$113.18Price Target Upside110.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.97
Revenue Forecast (FY)$7.14M
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationAnalyst notes that updated ACCESS II and Phase 2b data may demonstrate dose-dependent efficacy for aleniglipron, distinguishing it from competing oral GLP-1 therapies and strengthening clinical differentiation.
Commercial Opportunity And Strategic InterestAnalyst points to strong market demand for once-daily oral GLP-1 pills and a potential production cost advantage that could accelerate commercial uptake or make the asset an attractive acquisition target.
Safety And TolerabilityAnalyst highlights low treatment discontinuation and a favorable tolerability profile seen in Phase 2b, supporting better patient adherence compared with rivals that show higher gastrointestinal side effects.
Bears Say
Competitive Pressure From RivalsAnalyst cautions that strong tolerability and efficacy results from other amylin and oral GLP programs raise the performance bar, increasing competitive pressure on Structure's amylin and oral GLP candidates.
Execution And Trial Design RiskAnalyst flags execution risk around progressing to registrational Phase 3, emphasizing the need for regulatory alignment, robust titration strategies, and larger, well‑powered studies to validate efficacy.
Major Safety RiskAnalyst warns that the emergence of a major safety signal or a failure to achieve additional weight loss during extended treatment would materially undermine investor expectations and negatively affect the stock.
Structure Therapeutics, Inc. Sponsored ADR News
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $13.22 and its highest was $94.90 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $3.81B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is May 07, 2026 which is in 53 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Feb 26, 2026. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of -$0.057 by $0.227.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.4.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 70,841,810 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of $0.17 in its last earnings report, beating expectations of -$0.057. Following the earnings report the stock price went down -2.734%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$113.18 (110.57% Upside)
$113.18 (110.57% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 57.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.7%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
163.48%
12-Months-Change
Fundamentals
Return on Equity
-14.55%
Trailing 12-Months
Asset Growth
75.34%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
GPCR Stock 12 Month Forecast
Average Price Target
$113.18
▲(110.57% Upside)
Technical Analysis
Ownership Overview
9.26% Insiders
18.08% Mutual Funds
11.94% Other Institutional Investors
58.64% Public Companies and Individual Investors